US Stem Cell USRM · USD

Its shares trade under the ticker USRM. It has been listed since 19 February 2008. In the fiscal year to 31 December 2022, it reported revenue of $82,049 and a net loss of $2.9m. At that date it held total assets of $68,039 and shareholders' equity of −$14.7m.

U.S.Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The company is headquartered in Sunrise, Florida. The company went IPO on 2008-02-19. Stem Cell, Inc., formerly Bioheart, Inc., is a biotechnology company. The firm is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its MyoCell is a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. Its AdipoCell is a cell therapy with multiple possible treatment applications using autologous adipose cells. Its business includes the development of cell therapy products, as well as physician and patient-based regenerative medicine/cell therapy training services, and the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. The company operates through divisions, including US Stem Cell Training, Vetbiologics and US Stem Cell Clinic.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Mark BormanNon-Executive Chairman of the Board, since 2009
• Dr. William MurphyChairman Emeritus, since 2003
• Mr. Mike TomasPresident, Chief Executive Officer, Chief Financial Officer, Director, since 2003$327,279
• Mr. Sheldon AndersonDirector
• Mr. Gregory KnutsonDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.